

UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2023

Contents	Page No.
Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income	1 - 2
Unaudited Condensed Consolidated Statement of Financial Position	3
Unaudited Condensed Consolidated Statement of Changes in Equity	4
Unaudited Condensed Consolidated Statement of Cash Flows	5
Notes to the Interim Financial Report:-	
Part A - Explanatory Notes Pursuant to MFRS134	6 - 8
Part B - Explanatory Notes Pursuant to Appendix 9B of the Listing Requirements of Bursa Malaysia Securities Berhad	9 - 11



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2023

	3 months	ended	9 months ended	
	30/09/2023	30/09/2022	30/09/2023	30/09/2022
	RM'000	RM'000	RM'000	RM'000
Revenue	90,451	93,053	265,667	251,694
Cost of sales	(50,414)	(54,835)	(151,164)	(145,393)
Gross profit	40,037	38,218	114,503	106,301
Other income	879	4,010	6,033	6,972
Selling & Distribution expenses	(18,924)	(18,538)	(57,880)	(52,997)
Administrative expenses	(6,899)	(6,449)	(20,314)	(18,121)
Other expenses	(4,599)	(1,388)	(708)	(1,568)
Results from operating activities	10,494	15,853	41,634	40,587
Finance income	467	371	1,461	967
Finance cost	(719)	(378)	(1,589)	(1,253)
Share of result of associate	(56)	(32)	23	(42)
Profit before tax	10,186	15,814	41,529	40,259
Income tax expense	(4,173)	(4,393)	(11,849)	(10,975)
Profit for the period	6,013	11,421	29,680	29,284
Other comprehensive income, net of tax				
Items that may be reclassified subsequently to profit or loss				
Foreign currency translation differences for foreign operations	1,350	(800)	(1,535)	(1,087)
Total other comprehensive income / (expenses) for the period	1,350	(800)	(1,535)	(1,087)
Total comprehensive income for the period	7,363	10,621	28,145	28,197



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONTINUED)

FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2023

	3 months ended		9 month	s ended
	30/09/2023	30/09/2022	30/09/2023	30/09/2022
	RM'000	RM'000	RM'000	RM'000
Attributable to:				
Owners of the Company	5,978	11,076	29,171	28,666
Non-controlling interests	35	345	509	618
Profit for the period	6,013	11,421	29,680	29,284
Total comprehensive income attributable to:				
Owners of the Company	7,259	10,308	27,774	27,606
Non-controlling interests	104	313	371	591
Total comprehensive income for the period	7,363	10,621	28,145	28,197
Earnings per share (EPS) attributable to owners of the Company (sen):				
Basic EPS	4.22	7.85	20.63	20.34
Diluted EPS	4.21	7.85	20.58	20.32

Included in the profit for the period are:

	3 months ended		3 months ended 9 months ende	
	30/09/2023	30/09/2022	30/09/2023	30/09/2022
	RM'000	RM'000	RM'000	RM'000
				()
interest income	(467)	(371)	(1,461)	(967)
other income including investment income	(28)	(19)	(74)	(58)
interest expenses	719	378	1,589	1,253
depreciation and amortisation	3,913	3,851	11,711	11,531
provision for and (write back) / write off of receivables	575	(86)	1,366	291
writedown and (write back) / write off of inventories	516	374	1,887	828
foreign exchange loss or (gain)	3,119	(2,685)	(7,399)	(6,306)

The above consolidated statements of profit or loss and other comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2022.



Y.S.P. SOUTHEAST ASIA HOLDING BHD. (Company no : 200101017024 (552781-X)) (Incorporated in Malaysia) CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2023

ASSETS	As at 30/09/2023 RM'000 <i>Unaudited</i>	As at 31/12/2022 RM'000 Audited
Property, plant and equipment	163,707	134,719
Intangible assets	4,910	4,826
Investment in associates	281	258
Deferred tax assets	159	158
Non-current Assets	169,057	139,961
Inventories	135,452	117,259
Trade receivables	73,025	63,376
Other receivables	24,741	22,972
Amount due from affiliated companies	234	275
Amount due from an associate	1,003	438
Current tax assets	733	258
Cash & cash equivalents	115,987	129,506
Current Assets	351,175	334,084
TOTAL ASSETS	520,232	474,045
EQUITY AND LIABILITIES		
Characanital	454.424	450.050
Share capital	154,134	152,258
Other reserves	3,614	5,447
Retained earnings	229,532	214,454
Equity Attributable to Owners of the Company	387,280	372,159
Non-controlling interests	6,107	5,816
Total Equity	393,387	377,975
Deferred taxation	12,228	11,516
Loans and borrowings	36,253	13,451
Post-employment benefits	637	593
Lease liabilities	3,713	4,784
Non-current Liabilities	52,831	30,344
Trade payables	22,214	16,707
Other payables	22,846	22,630
Refund liability	1,878	1,928
Amount due to affiliated companies	6,617	8,193
Loans and borrowings	12,030	10,639
Current tax liabilities	4,985	2,233
Lease liabilities	3,444	3,396
Current Liabilities	74,014	65,726
Total Liabilities	126,845	96,070
TOTAL EQUITY AND LIABILITIES	520,232	474,045
Net assets per share attributable to owners of the Company (RM)	2.73	2.64

The above consolidated statement of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2022.



Y.S.P. SOUTHEAST ASIA HOLDING BHD. (Company no : 200101017024 (552781-X)) (Incorporated in Malaysia) UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2023

← Attributable to owners of the Company −
← Non-distributable → Distributable

RM'000	Share capital	Exchange fluctuation reserve	Share option reserve	Retained earnings	Total	Non- controlling interest	Total equity
At 1 January 2022	151,963	662	2,675	191,202	346,502	5,361	351,863
Foreign currency translation differences for foreign operations		(1,060)			(1,060)	(27)	(1,087)
Total other comprehensive income for the period		(1,060)			(1,060)	(27)	(1,087)
Profit for the period	_	(1,000)	_	28,666	28,666	618	29,284
Total comprehensive income for the period	-	(1,060)	-	28,666	27,606	591	28,197
Dividends to owners of the Company	-	_	-	(11,281)	(11,281)	-	(11,281)
Dividends to non-controlling interest	-	-	-	-	-	(40)	(40)
Issuance of ordinary shares pursuant to ESOS	206	-	-	-	206	-	206
Total transactions with owners of the Company	206	-	-	(11,281)	(11,075)	(40)	- (11,115)
Transfer to share capital for share options exercised	38	-	(38)	-	-	-	-
At 30 September 2022	152,207	(398)	2,637	208,587	363,033	5,912	368,945
At 1 January 2023	152,258	2,888	2,559	214,454	372,159	5,816	377,975
Foreign currency translation differences for foreign operations		(1,397)			(1,397)	(138)	(1,535)
Total other comprehensive income for the period		(1,397)			(1,397)	(138)	(1,535)
Profit for the period	_	(1,001)	_	29,171	29,171	509	29,680
Total comprehensive income for the period	-	(1,397)	-	29,171	27,774	371	28,145
Dividends to owners of the Company Dividend to non-controlling interest	-	-	-	(14,169)	(14,169)	- (80)	(14,169)
Issuance of ordinary shares pursuant to ESOS	1,516	_	_	_	1,516	(00)	1,516
Share option granted under ESOS forfeited		_	(76)	76		_	- 1,010
Total transactions with owners of the Company	1,516	-	(76)	(14,093)	(12,653)	(80)	(12,733)
Transfer to share capital for share options exercised	360	-	(360)	-	-	-	-
At 30 September 2023	154,134	1,491	2,123	229,532	387,280	6,107	393,387

The above consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2022.



UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2023

	9 months e	nded
	30/09/2023	30/09/2022
	RM '000	RM '000
Cash flows from operating activities		
Profit before tax	41,529	40,259
Other adjustments	8,982	8,583
Operating profit before changes in working capital	50,511	48,842
Net change in current assets	(33,306)	(23,408)
Net change in current liabilities	5,740	15,726
Cash generated from operations	22,945	41,160
Tax paid	(8,902)	(3,348)
Net cash generated from operating activities	14,043	37,812
Cash flows from investing activities		
Interest received	1,461	967
Proceeds from disposal of property, plant and equipment	(146)	191
Purchase of property, plant and equipment	(34,468)	(2,449)
Purchase of intangible assets	(141)	(6)
Net cash used in investing activities	(33,294)	(1,297)
Cash flows from financing activities		
Interest paid	(1,589)	(1,119)
Dividends paid	(14,169)	(11,281)
Dividend to non-controlling interest	(80)	(40)
Proceeds from issuance of ordinary shares-ESOS, net of expenses	1,516	244
Drawdown of term loans / revolving credit	26,350	-
Repayment of term loans / hire purchase creditors	(5,277)	(19,557)
Payment of lease liabilities	(2,783)	(2,755)
Net cash (used in) / from financing activities	3,968	(34,508)
Net increase in cash and cash equivalents	(15,283)	2,007
Effect on foreign exchange rate changes	1,764	1,600
Cash and cash equivalents at 1 January	129,506	120,401
Cash and cash equivalents at 30 September	115,987	124,008
	30/09/2023	30/09/2022
	RM '000	RM '000
Composition of cash and cash equivalents		
Cash and bank balances	59,898	53,976
Fixed deposits with licensed banks	56,089	70,032
	115,987	124,008



Y.S.P. SOUTHEAST ASIA HOLDING BHD. (Company no : 200101017024 (552781-X)) (Incorporated in Malaysia) NOTES TO THE INTERIM FINANCIAL REPORT - 30 SEPTEMBER 2023

Basis of Preparation

The condensed consolidated interim financial statements are unaudited and have been prepared in accordance with the requirements of MFRS 134 and IAS 34 "Interim Financial Reporting" and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements for the year ended 31 December 2022. The explanatory notes attached to the condensed report provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2022.

Changes in Accounting Policies

The accounting policies and method of computation adopted for the condensed interim financial statements are consistent with those adopted for the annual audited financial statements for the year ended 31 December 2022.

Standards, Amendments and Annual Improvements to Standards that are applicable and effective to the Group beginning on 1 January 2023 are as follows:

- MFRS 17. Insurance Contracts
- Amendments to MFRS 17, Insurance Contracts Initial application of MFRS 17 and MFRS 9 Comparative Information
- Amendments to MFRS 101, Presentation of Financial Statements Classification of Liabilities as Current or Non-current and Disclosures of Accounting Policies
- Amendments to MFRS 108, Accounting Policies, Changes in Accounting Estimates and Errors Definition of Accounting Estimates
 Amendments to MFRS 112, Income Taxes Deferred Tax related to Assets and Liabilities arising from a Single Transaction and International Tax Reform Pillar Two Model Rules

Standards, Amendments and Annual Improvements to Standards that are applicable and effective to the Group beginning on 1 January 2024 are as follows:

- Amendments to MFRS 16, Leases Lease Liability in a Sale and Leaseback
- Amendments to MFRS 101, Presentation of Financial Statements Non-current Liabilities with Covenants and Classification of Liabilities as Current or Non-current
 Amendments to MFRS 107, Statement of Cash Flows and MFRS 7, Financial Instruments: Disclosures Supplier Finance Arrangements

Standards, Amendments and Annual Improvements to Standards that are applicable and effective to the Group beginning on or after a date yet to be confirmed are as

• Amendments to MFRS 10, Consolidated Financial Statements and MFRS 128, Investments in Associates and Joint Ventures - Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

The Group and the Company plan to apply the abovementioned accounting standards, interpretations and amendments:

- from the annual period beginning on 1 January 2023 for the accounting standard and amendments that are effective for annual periods beginning on or after 1 January 2023, except for MFRS 17 and amendments to MFRS 17 which are not applicable to the Group.
- from the annual period beginning on 1 January 2024 for the amendments that are effective for annual periods beginning on or after 1 January 2024.

The initial application of the abovementioned accounting standards, interpretations and amendments is not expected to have any material financial impact to the current period and prior period financial statements of the Group and the Company.

Auditors' Report on Preceding Annual Financial Statements

The auditors' report on the audited financial statements for the year ended 31 December 2022 was not qualified.

Seasonal or Cyclical Factors

The Group's operations are not materially affected by any seasonal or cyclical factors.

Unusual Items due to their Nature, Size or Incidence

There were no unusual items affecting assets, liabilities, equity, net income or cash flows during the quarter and nine months ended 30 September 2023.

Material Changes in Estimates

There were no changes in estimates that have any material effect on the quarter and nine months ended 30 September 2023.

During the nine months ended 30 September 2023, the Company has issued 716,000 unit of ordinary shares pursuant to the exercise of Company's ESOS.

Exercise Price RM	No. of Shares Issued	Cash Proceeds RM
1.82	302,000	549,640
1.89	112,000	211,680
2.40	102,000	244,800
2.55	200,000	510,000

A8 Dividends Paid

At the 22nd Annual General Meeting held on 23 May 2023, the shareholders have approved the payment of a final single-tier ordinary dividend of 7.5 sen per ordinary share and a final single-tier special dividend of 2.5 sen per ordinary share in respect of financial year ended 31 December 2022 which was paid on 25 July 2023.

A9 Segment Information

The Group is organised based on three major business segments as described below. The basis of segmentation was based on information reported internally to the Managing Director of the Group.

Performance is measured based on segment profit before tax and the total of segment assets are measured based on all assets (including goodwill) of a segment that are reviewed by the Group. Segment total asset is used to measure the return of assets of each segment.

There are no changes in the segment reported in the last audited financial statements.

Year-to-date ended 30 September 2023	Investment holding RM'000	Trading RM'000	Manufacturing RM'000	Inter-company Elimination RM'000	Total RM'000
Revenue from external customer	-	45,658	220,009	-	265,667
Inter-segment revenue	17,155	536	29,875	(47,566)	-
Total revenue	17,155	46,194	249,884	(47,566)	265,667
Segment profit before tax	20,673	5,938	35,692	(20,774)	41,529
Segment assets	200,983	72,350	477,302	(230,403)	520,232
Segment liabilities	3,451	41,833	247,896	(166,335)	126,845
Year-to-date ended 30 September 2022	Investment holding	Trading	Manufacturing	Inter-company Elimination	Total

Year-to-date ended 30 September 2022	Investment holding RM'000	Trading RM'000	Manufacturing RM'000	Inter-company Elimination RM'000	Total RM'000
Revenue from external customer	-	40,795	210,899	-	251,694
Inter-segment revenue	12,808	881	35,691	(49,380)	-
Total revenue	12,808	41,676	246,590	(49,380)	251,694
Segment profit / (loss) before tax	16,986	3,556	35,195	(15,478)	40,259
Segment assets	202,534	67,281	426,043	(227,185)	468,673
Segment liabilities	3,403	39,930	211,989	(155,594)	99,728

	i otal re	venue
Geographical segments	30/09/2023	30/09/2022
	RM'000	RM'000
Malaysia	192,242	185,356
Singapore	28,006	24,367
Vietnam	15,094	17,192
Philippines	1,600	1,896
Cambodia	7,528	6,259
Myanmar	1,537	517
Brunei	2,522	2,352
Indonesia	4,527	3,745
Thailand	1,134	685
Africa	4,651	3,451
Other countries	6,826	5,874
	265,667	251,694

Investment holding 9M23 vs 9M22

Investment holding segment profit before tax posted higher at RM20.7 million in 9M23 compared to RM17.0 million in 9M22 mainly attributed to higher dividend income received from subsidiary companies in 9M23.

Trading 9M23 vs 9M22

Trading segment posted a higher profit before tax of RM5.9 million in 9M23 compared to a profit before tax of RM3.6 million in 9M22 mainly driven by increase sales of the pharmaceutical products in 9M23.

Manufacturing 9M23 vs 9M22

Manufacturing segment posted revenue of RM249.9 million in 9M23, 1.3% higher than the revenue of RM246.6 million reported in 9M22. The profit before tax for 9M23 was marginally higher at RM35.7 million compared to RM35.2 million in 9M22 due to lower cost margin in product mix in 9M23.

A10 Valuations of Property, Plant and Equipment

Property, plant and equipment of the Group are stated at cost less accumulated depreciation and any accumulated impairment losses where applicable.

There is no revaluation of property, plant and equipment during the quarter under review.

A11 Subsequent Events

There were no changes in the composition of the Group during the quarter under review.

A12 Changes in the Composition of the Group

There were no changes in the composition of the Group during the quarter under review.

A13 Contingent Liabilities

There were no significant changes in contingent liabilities since 31 December 2022.

A14 Capital Commitment

Capital commitment expenditure not provided for in the condensed report as at the end of the financial period were as follows:

Contracted but not provided for RM'000

Plant & machinery and other assets

8,742

A15 Related Party Transactions

Significant related party transactions are as follows:

	9 months	ended
Corporation related to substantial shareholder	30/09/2023 RM'000	30/09/2022 RM'000
Purchase of pharmaceutical products Sales of raw materials Consultancy fees payable	13,478 (329) 130	9,999 (433) 79
Companies in which certain Directors have interest		
Purchase of raw materials	4,658	1,708
Sales of pharmaceutical products	(725)	(656)

A16 Financial Instruments

The carrying amounts of cash and cash equivalents, short term receivables and payables and short-term borrowings approximate their fair values due to the relatively short term nature of these financial instruments.

The fair values of other financial assets and liabilities not carried at fair value, together with the carrying amounts shown in the statements of financial position, are as follows:

	As at 30/09/2023		As at 31/12/2022	
	Carrying amount	Fair value	Carrying amount	Fair value
	RM'000	RM'000	RM'000	RM'000
Long term loans and borrowings	33,927	27,313	11,526	11,106
Long term hire purchase creditors	2,326	2,234	1,925	1,788

PART B - EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

B1 Review of Performance

	3 months ended Variance		9 months ended		Variance			
	30/09/2023 RM'000	30/09/2022 RM'000	RM'000	%	30/09/2023 RM'000	30/09/2022 RM'000	RM'000	%
Revenue	90,451	93,053	(2,602)	(2.8)	265,667	251,694	13,973	5.6
Operating profit	10,494	15,853	(5,359)	(33.8)	41,634	40,587	1,047	2.6
Profit before interest and tax	10,438	15,821	(5,383)	(34.0)	41,657	40,545	1,112	2.7
Profit before tax	10,186	15,814	(5,628)	(35.6)	41,529	40,259	1,270	3.2
Profit after tax	6,013	11,421	(5,408)	(47.4)	29,680	29,284	396	1.4
Profit attributable to owners of the Company	5,978	11,076	(5,098)	(46.0)	29,171	28,666	505	1.8

The Group's revenue was RM265.7 million, 5.6% higher than the RM251.7 million recorded in the same period last year mainly due to increase sales from domestic and export market.

The Group recorded a profit before tax of RM41.5 million compared to RM40.3 million in the same period last year mainly due to increase productivity and higher sales from domestic and overseas market for the pharmaceutical products for the nine months ended 30 September 2023.

B2 Comparison with the Preceding Quarter's Results

	Qtr 3	Qtr 2	Variance		
	(30/09/2023) RM'000	(30/06/2023) RM'000	RM'000	%	
Revenue	90,451	79,628	10,823	13.6	
Operating profit	10,494	16,116	(5,622)	(34.9)	
Profit before interest and tax	10,438	16,144	(5,706)	(35.3)	
Profit before tax	10,186	16,190	(6,004)	(37.1)	
Profit after tax	6,013	12,531	(6,518)	(52.0)	
Profit attributable to owners of the Company	5,978	12,378	(6,400)	(51.7)	

The Group's recorded a higher revenue of RM90.5 million, an increase of 13.6% for the current quarter compared to RM79.6 million for the immediate preceding quarter (2Q23") which was mainly due to increase sales from domestic and export market during the quarter under review.

The Group posted a lower profit before tax of RM10.2 million compared to RM16.2 million for the immediate preceding quarter mainly attributed to lower unrealised foreign exchange gain during the quarter under review.

B3 Prospects of the Group

Although domestic demand and export market for pharmaceutical products continued to grow, its pace has moderated, and therefore, to improve efficiency in productivity and expenditure are crucial to maintain the growth momentum in FY2023 despite the rising cost, global economy challenges and uncertainty in pharmaceutical industry.

The Group's revenue increased by 5.6% to RM265.7 million for the nine months ended 30 September 2023 compared to RM251.7 million reported in the same period last year. The Group's profit before tax increased 3.2% to RM41.5 million from RM40.3 million a year ago due to higher sales from domestic demand and overseas market for pharmaceutical products.

The Group remains optimistic that the growth prospects of the pharmaceutical products will continue in FY2023 and will take cautious approaches in reviewing and monitoring market conditions to be in line with changing market trends.

B4 Profit Forecast or Profit Guarantee

There were no profit forecast or profit guarantee issued by the Group.

B5 Taxation

Details of taxation are as follows :-

	3 months ended		9 months ended	
	30/09/2023 RM'000	30/09/2022 RM'000	30/09/2023 RM'000	30/09/2022 RM'000
Current tax	3,938	3,874	11,067	9,746
Deferred tax	235	519	782	1,229
	4,173	4,393	11,849	10,975

Income tax is calculated at the Malaysian statutory tax rate of 24%. (2022: 24%)

The Group's effective tax rate for the current quarter was higher than the statutory tax rate principally due to certain expenses which were not deductible for tax purposes.

B6 Corporate Proposals

There were no corporate proposals announced by the Company as at the reporting date.

B7 Borrowings and Debt Securities

The details of the Group borrowings as at 30 September 2023 are as follows :

30 September 2023		Denominated in Foreign Currency	RM Equivalent
		SGD'000	RM'000
	Current		
	Secured revolving credit Secured bank loans:	-	4,400
	- Domestic	_	4,417
	- Foreign	-	-,
	Hire purchase creditor:		
	- Domestic	-	3,163
	- Foreign	15	50
		15_	12,030
	Non-current		
	Secured bank loans:		
	- Domestic	-	33,927
	- Foreign Hire purchase creditor:	-	-
	- Domestic	_	2,291
	- Foreign	10	35
		10	36,253
	Total borrowings	25	48,283
	•		10,200
31 December 2022		Denominated in Foreign Currency	RM Equivalent
		SGD'000	RM'000
	Current		
	Secured revolving credit	-	4,400
	Secured bank loans:		
	- Domestic	-	3,060
	- Foreign	-	-
	Hire purchase creditor:		
	- Domestic	-	3,131
	- Foreign	15	48
		15	10,639
	Non-current		
	Secured bank loans:		
	- Domestic	-	11.526
	- Domestic - Foreign	-	11,526
	- Domestic - Foreign Hire purchase creditor:		11,526
	- Foreign		
	- Foreign <u>Hire purchase creditor:</u>	-	-
	- Foreign <u>Hire purchase creditor:</u> - Domestic	-	- 1,854 71
	- Foreign <u>Hire purchase creditor:</u> - Domestic	- - 22	1,854

As at the reporting date, the Group had not issued any debt securities.

B8 Material Litigation

There was no material litigation against the Group as at the reporting date.

B9 Proposed Dividend

Apart from that disclosed in Note A8, there was no dividend proposed in the current quarter under review.

B10 Earnings Per Share

		3 months ended		9 months ended	
		30/09/2023	30/09/2022	30/09/2023	30/09/2022
i)	Basic Earnings Per Share				
	Profit attributable to owners of the Company (RM'000)	5,978	11,076	29,171	28,666
	Weighted average number of ordinary shares in issue ('000)	141,704	141,013	141,375	140,955
		4.22	7.85	20.63	20.34
ii)	Diluted Earnings Per Share				
	Profit attributable to owners of the Company (RM'000)	5,978	11,076	29,171	28,666
	Weighted average number of ordinary shares in issue ('000)	141,704	141,013	141,375	140,955
	Effect of dilution-Share options ('000)	273	169	377	140
	Adjusted weighted average number of ordinary shares in issue ('000)	141,977	141,182	141,752	141,095
	Diluted Earnings Per Share (sen)	4.21	7.85	20.58	20.32

The basic and diluted earnings per share are calculated by dividing profit for the period attributable to owners of the Company over the weighted average number of ordinary shares in issue.